相关实验视频
Updated: Jun 13, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
MiniMed 780G系统在减轻依赖月经周期的血糖变异性方面的性能
Yasmine Ibrahim Elhenawy1, Mohamed S Abdel Kader2, Rasha A Thabet1
1Paediatric and Adolescent Diabetes Unit (PADU), Department of Paediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Diabetes, obesity & metabolism
|September 9, 2024
概括
MiniMed 780G系统有效地管理了1型糖尿病女性在整个月经周期中的血糖波动. 这种先进的混合闭环系统保持了目标葡萄糖水平,在所有循环阶段改善了射程时间.
科学领域:
- 内分泌学 在内分泌学.
- 代谢科学 代谢科学
- 糖尿病 技术 技术
背景情况:
- 月经周期阶段对1型糖尿病妇女的血糖控制有显著影响.
- 了解这些变异对于优化糖尿病管理至关重要.
研究的目的:
- 分析在不同月经周期阶段的血糖变化和胰岛素需求.
- 评估MiniMed 780G系统在整个月经周期中控制血糖变化的有效性.
主要方法:
- 一项试点研究涉及15名患有1型糖尿病和定期月经的青少年和年轻成年女性.
- 在为期3个月的开放循环期间 (OLP) 和为期3个月的先进混合闭环期间 (AHCL) 分析了连续血糖监测数据.
- 月经周期阶段被归类为卵泡或白色细胞.
主要成果:
- 在OLP期间,与卵泡阶段相比,在质阶段,范围内的时间减少,范围以上的时间增加.
- 在AHCL期间,毛囊和质阶段之间的时间范围是可比的,而不会增加低血糖.
- 自动基础和自动校正胰岛素输送在AHCL期间的质阶段增加.
结论:
- MiniMed 780G系统的自动算法成功地减轻了与月经周期相关的血糖变化.
- 该系统实现了推的血糖指数结果,在整个月经周期中保持了超过70%的时间范围.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
157
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
157
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Hypoglycemia and Glucagon
216
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
216
Pulse rhythm
771
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
771
Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
Oral Hypoglycemic Agents: Glinides
147
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
147

